"Heptovax" - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Tertomotide (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms HeptoVax
- Sponsors Pharmexa
- 17 Dec 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 19 Nov 2007 Interim results on the first 21 patients have been reported; final data expected by the end of the second quarter in 2008.
- 06 Nov 2007 Status changed from recruiting to in progress. Overall, 40 patients have been enrolled. Results from the first 21 patients are expected to be reported by the end 0f 2007.